JSC Pharmasyntez has been in the pharmaceutical market since 1997. The company is focused on development and production of pharmaceutical products for the treatment of socially significant diseases, such as TB, HIV/AIDS, hepatitis, oncological and blood diseases. The company is one of the largest manufacturers of antibiotics in Russia.
The company's mission is
• to produce effective drugs of high quality demanded by the modern medicine;
• to develop innovative pharma products;
• to increase the share of domestic drugs on the Russian market by substitution of imported analogues.
Pharmasyntez group structure:
• Irkutsk facility – JSC Pharmasyntez
• Ussuriysk facility – LLC EAST-PHARM
• Tyumen facility – LLC Pharmasyntez-Tyumen
• Bratsk facility – LLC BratskChemSyntez
• Saint Petersburg facility – JSC Pharmasyntez-Nord
Pharmasyntez is one of the top 10 leading pharmaceutical companies in Russia in terms of production growth and one of the top 3 fast-developing pharmaceutical enterprises on the Russian market.
The output of the Pharmasyntez group is 50 million packs per year
Its annual turnover: more than 10 billion rubles
Company's staff: 1500 highly skilled specialists
Three plants of the Pharmasyntez group in Irkutsk, Ussuriysk, and Tyumen are now producing 113 pharmaceutical products of different dosage forms and strengths: capsules, tablets, granules, infusion solutions, sterile dry powders and solutions for injection.
A research and production complex for development and manufacture of anticancer and biotech drugs is being constructed in St. Petersburg; the 1st stage of construction is ongoing now; it is scheduled for commissioning in 2018.
In Bratsk, the construction of a plant for manufacturing of active pharmaceutical ingredients is about to be completed, the full cycle production is scheduled for 2017, this will allow to provide a full cycle production of the company’s drugs.
To implement these plans, Pharmasyntez invests more than 5 billion rubles in development of its own production facilities.
Development of innovative pharma products and their introduction into a manufacturing process is a priority of the company. Annually, the Company invests up to 500 mln. rubles in scientific researches. The company is continuously working towards finding New Molecular Entities for combating TB, HIV, and other diseases.
Annually, the Company synthesizes 300 to 500 new molecules.
Several years ago, a New Chemical Entity was developed for the treatment of multi-drug resistant tuberculosis (MDR-TB), and in 2015 it was listed as a VEN drug.
The phase II clinical trial of a radically new, first-of-its class pharmaceutical product for the prevention of adhesive disease is ongoing now.